https://www.selleckchem.com/pr....oducts/gsk2879552-2h
4% 81.8%, hazard ratio = 0.66, 95% CI = 0.39-1.11) as well as disease-specific and recurrence-free survival. In addition, ESD was associated with fewer adverse events (19.8 % 44.0%, odds ratio = 0.3, 95% CI = 0.23-0.39). For superficial esophageal squamous cancer, ESD may be considered as the primary treatment of for mucosal lesions, and additional treatment should be available for submucosal invasive cancers. For superficial esophageal squamous cancer, ESD may be considered as the primary treatment of for mucosal lesions, and a
Like
Comment
Share
